Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review

Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review James R. Rigas Oncologist 2004; 9(Suppl 2): 16-23 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the rationale for and use of taxanes in NSCLC. Identify key efficacy findings from the four large randomized trials assessing platinum-taxane combinations in advanced NSCLC. Discuss adverse event and quality-of-life results from four large randomized trials assessing platinum-taxane combinations in advanced NSCLC. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: May 25, 2004 Most Recent Review: May 25, 2004* Most Recent Update: May 25, 2004 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Microtubule Stabilization in the Treatment of Solid Tumors: Role of the Taxanes.